Membrane Protein Screening Array, MPSA AB5000

De-risk Off-Target Interactions in Antibody Drug Development

Membrane Protein Antibody Discovery –MPSA-AB5000 Overview

Membrane Proteins Screening Array AB5000 service

MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]

MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]

The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. The lack of suitable methods to identify the targets of functional antibodies and ligands result in drug safety accidents and the abandonment of previous studies.

KYinno’s Membrane Proteins Screening Array (MPSA-AB5000) is an excellent solution for antibody specificity screening which enable early off-target screening and can de-risk the antibody drug development program.

MPSA-AB5000 Screening Workflow

The MPSA-AB5000 platform follows a structured approach to ensure accurate target validation:

  1. Target Identification & Specificity Screening – High-throughput evaluation of antibody interactions.
  2. Membrane Protein Library Screening – Testing against 5,000+ human membrane proteins for comprehensive coverage.
  3. Luciferase Reporter System Detection – Providing real-time, wash-free signal amplification for precise binding analysis.
  4. Data Analysis & Risk Assessment – Evaluating off-target risks and binding affinity for safer therapeutic development.
  5. Comprehensive Reporting – Delivering detailed reports with validated binding specificity and functional impact assessments.

This process enables researchers to identify unintended targets early, minimizing risks before advancing to clinical development.

Advantages of MPSA-AB5000 for Membrane Protein Antibody Discovery

Our MPSA-AB5000 platform offers significant benefits for antibody validation and therapeutic screening:

Full Coverage of Human Membrane Protein Library

human membrane protein library  

  • The MPSA-AB5000 makes use of more than 5000 unique human membrane protein, including receptors, transporters, enzymes, miscellaneous, and others.
  • Natively expressed in live cells ensuring native protein conformation.

High Sensitivity Reporter System Detection

high sensitivity reporter system detection infographic

  • Wash-free strategy reduces false negatives.
  • Signal amplification makes large discrimination.
  • High throughput microplate system guarantees best stability and credibility.

Compatibility with Different Types of Biologic Therapeutics:

compatibility with different types of biologic therapeutics infographic

 

  • MPSA-AB5000 is compatible with monoclonal antibodies, bispecific antibodies, ADC, orphan protein and antibody, as well as CAR-T cell therapies.

Successfully Screened Off-target Molecules

screened off-target molecules infographic

  • Ultrashort turnaround for data report
  • Competitively priced
MPSA-AB5000 is rapid, simple and highly sensitive by measuring binding via reporter cell lines and can determine specificity and preclinical safety of biotherapeutics conveniently. Incorporating early specificity testing, MPSA-AB5000 reduces the risk of late-stage failures and supports successful IND applications.

Expert Support Throughout Your Screening Process

Our scientific team provides comprehensive support at every stage of membrane protein screening:

  • Pre-Screening Consultation – Selecting the right approach based on antibody target profiles.
  • Data Analysis & Interpretation – Providing in-depth reports with actionable insights.
  • Risk Assessment & IND Strategy – Helping researchers mitigate off-target interactions for regulatory approval.
  • Custom Study Design – Tailoring assays to meet specific research objectives.

We work closely with research teams to ensure that each antibody candidate undergoes rigorous validation before advancing to preclinical and clinical studies.

How to Get Started with Kyinno Bio

Enhance your membrane protein antibody discovery with Kyinno Bio’s MPSA-AB5000 platform. Our high-throughput screening system ensures accurate target validation and de-risks antibody drug development. We provide customized screening solutions for monoclonal antibodies, bispecifics, ADCs, and CAR-T therapies, ensuring high specificity and minimized off-target effects. Contact us today to discuss your antibody validation needs.

All Antibody Discovery Services

BiSpecific Antibodies

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heighten specificity, expand treatment options, and pave the way for future medical advancements.

Using antibodies with high specificity, Membrane Protein Antibody Discovery MPS AB5000 guarantee precise binding targets for CAR-T cells and biologics. This platform is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.

ai drug discovery service

AI Drug Discovery

AI Drug Discovery leverages advanced algorithms to revolutionize therapeutic antibody development by streamlining the traditionally cumbersome process.  Our AI-driven neural networks identify precise relationships between antibody and antigen structures, enabling the virtual generation of innovative antibody drugs.